EASL-ILCA肝内胆管癌管理临床实践指南
肝内胆管癌是第二常见的原发性肝癌,全球发病率上升,因起病隐匿、侵袭性强和治疗抵抗导致死亡率高。ILCA和EASL理事会委托国际专家制定基于证据的指南,涵盖诊断、预后和治疗管理,以应对临床、基因组和分子异质性带来的挑战。
要点
- 肝内胆管癌是第二常见原发性肝癌,全球发病率上升且死亡率高。
- 早期诊断、分子特征分析、准确分期和个体化多学科治疗是当前挑战。
- ILCA和EASL委托国际专家制定基于证据的指南以规范管理。
核心结论
- ILCA和EASL理事会委托国际专家制定了针对肝内胆管癌诊断、预后和治疗管理的基于证据的指南。
研究设计与样本
- EASL-ILCA临床实践指南,由ILCA和EASL理事会委托国际专家制定。
主要发现
- 肝内胆管癌是第二常见的原发性肝癌,全球发病率正在上升。
- 肝内胆管癌因起病隐匿、高度侵袭性和治疗抵抗而死亡率高。
- 肝内胆管癌在临床、基因组、表观遗传和分子水平高度异质,常使管理难以成功。
- 近年来在分子特征分析、手术管理和靶向治疗方面取得了进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intrahepatic cholangiocarcinoma (iCCA) develops inside the liver, between bile ductules and the second-order bile ducts. It is the second most frequent primary liver cancer after hepatocellular carcinoma, and its global incidence is increasing. It is associated with an alarming mortality rate owing to its silent presentation (often leading to late diagnosis), highly aggressive nature and resistance to treatment. Early diagnosis, molecular characterisation, accurate staging and personalised multidisciplinary treatments represent current challenges for researchers and physicians. Unfortunately, these challenges are beset by the high heterogeneity of iCCA at the clinical, genomic, epigenetic and molecular levels, very often precluding successful management. Nonetheless, in the last few years, progress has been made in molecular characterisation, surgical management, and targeted therapy. Recent advances together with the awareness that iCCA represents a distinct entity amongst the CCA family, led the ILCA and EASL governing boards to commission international experts to draft dedicated evidence-based guidelines for physicians involved in the diagnostic, prognostic, and therapeutic management of iCCA.
引用
- EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023. PMID: 37084797. doi:10.1016/j.jhep.2023.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。